Yazar "Aras, MR" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • [ X ]
    Öğe
    An investigation of the predictive markers that can be used in the differentiation of benign and malignant lymphadenopathy
    (BAYRAKOL MEDICAL PUBLISHER, 2025) Yılmaz, F; Yıldız, A; Aras, MR; Kalkışım, HK; Demircan, A; Öztürk, HBA; Albayrak, M
    Aim: Lymphadenopathy (LAP) can develop for many infectious, rheumatological, immunological, and hematological reasons. The most important point for patients presenting with LAP is the decision-making for further tests to identify who should undergo a biopsy and who should be followed up. This study aimed to investigate predictive markers that can be used to differentiate benign and malignant LAP. Material and Methods: The study included 274 patients who presented at the Hematology Polyclinic with a diagnosis of LAP. Markers were investigated to determine which affected prognosis in patients with a histopathological benign or malignant LAP diagnosis. Results: Age, male gender, ferritin, lactate dehydrogenase (LDH), C-reactive protein (CRP), LAP located in the neck, thorax, and abdomen, the size of LAP situated in the neck, and the presence of splenomegaly, were determined at statistically significantly higher rates, and hemoglobin, hematocrit, platelet count, plateletcrit (PCT), and folate were statistically significantly lower in the group with malignant LAP. The results of multivariate analysis showed that age, gender, PCT, sedimentation value, thorax LAP, and inguinal LAP were independently significant in the differentiation of patients with benign and malignant LAP. Discussion: LAP is a frequently encountered pathology but biopsy and further tests may not be appropriate for every patient in terms of cost and workload. Therefore, predictive parameters will be of guidance to the clinician at the stage of decision-making. These parameters will avoid tiring the patient and the doctor with respect to unnecessary further tests, and the chance of early diagnosis will not be missed if it is a malignant process.